Mohamed Benchekroun

Mohamed Benchekroun is an experienced R&D Medicinal Chemist with a strong background in medicinal and pharmaceutical chemistry. Currently serving at AELIS FARMA since January 2022, Mohamed focuses on the discovery and development of first-in-class CB1-SSi for various CNS disorders. Previous roles include Research Scientist in Medicinal Chemistry at OXELTIS and Research Fellow in Medicinal Chemistry at institutions such as Cnam, CNRS, and the University of Sussex, where expertise encompasses the synthesis and pharmacological evaluation of compounds targeting oncology and neurodegenerative diseases. Mohamed holds a PhD in Medicinal and Pharmaceutical Chemistry from Université de Franche-Comté, complemented by Master's degrees in Organic Chemistry from Paris-Sud University. Teaching experience includes instruction in organic and medicinal chemistry at the university level.